Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-08-08
2006-08-08
Nolan, Patrick J. (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S130100, C435S335000
Reexamination Certificate
active
07087726
ABSTRACT:
The present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention further relates to the use of such anti-IFN-α antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-α, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE).
REFERENCES:
patent: 4289690 (1981-09-01), Pestka
patent: 4341761 (1982-07-01), Ganfield
patent: 4423147 (1983-12-01), Secher
patent: 4474754 (1984-10-01), Shimizu
patent: 4514507 (1985-04-01), Secher
patent: 4824432 (1989-04-01), Skurkovich
patent: 4885166 (1989-12-01), Meyer et al.
patent: 4902618 (1990-02-01), Berg
patent: 4973556 (1990-11-01), Bove
patent: 5055289 (1991-10-01), Frincke
patent: 5073491 (1991-12-01), Familletti
patent: 5196323 (1993-03-01), Bodo
patent: 5240864 (1993-08-01), Koga
patent: 5317089 (1994-05-01), Adolf
patent: 5503828 (1996-04-01), Testa
patent: 5516515 (1996-05-01), Vellucci
patent: 5626843 (1997-05-01), Skurkovich
patent: 5676942 (1997-10-01), Testa
patent: 5780027 (1998-07-01), Maroun
patent: 5789551 (1998-08-01), Pestka
patent: 5869293 (1999-02-01), Pestka
patent: 5888511 (1999-03-01), Skurkovich
patent: 5919453 (1999-07-01), Benoit
patent: 6001589 (1999-12-01), Pestka
patent: 6117423 (2000-09-01), Berg
patent: 6136309 (2000-10-01), Novick
patent: 6150503 (2000-11-01), Pestka
patent: 6180370 (2001-01-01), Queen et al.
patent: 6299870 (2001-10-01), Pestka
patent: 6300474 (2001-10-01), Pestka
patent: 6312924 (2001-11-01), Presnell
patent: 6333032 (2001-12-01), Skurkovich
patent: 6410697 (2002-06-01), Berg
patent: 6433145 (2002-08-01), LaFleur
patent: 6514753 (2003-02-01), Pestka
patent: 6548056 (2003-04-01), Presnell
patent: 6747131 (2004-06-01), Pestka
patent: 6827934 (2004-12-01), Co et al.
patent: 2001/0012514 (2001-08-01), Skurkovich
patent: 2002/0192748 (2002-12-01), Rastelli
patent: 2003/0044410 (2003-03-01), Skurkovich
patent: 2003/0138404 (2003-07-01), Maroun
patent: 2003/0147581 (2003-08-01), Doi
patent: 2003/0147889 (2003-08-01), Tovey
patent: 2004/0067888 (2004-04-01), Tovey
patent: 2004/0105841 (2004-06-01), Pestka
patent: 2004/0110715 (2004-06-01), Escary
patent: 2004/0126799 (2004-07-01), Escary
patent: 2004/0132139 (2004-07-01), Escary
patent: 2004/0142431 (2004-07-01), Escary
patent: 2004/0203118 (2004-10-01), Escary
patent: 1306961 (1992-09-01), None
patent: 267 392 (1990-12-01), None
patent: 276 203 (1992-04-01), None
patent: 276 204 (1992-04-01), None
patent: 231007 (1985-12-01), None
patent: 254593 (1988-03-01), None
patent: 265291 (1989-03-01), None
patent: 277087 (1990-03-01), None
patent: 279266 (1990-05-01), None
patent: 279317 (1990-05-01), None
patent: 279546 (1990-06-01), None
patent: 279547 (1990-06-01), None
patent: 279548 (1990-06-01), None
patent: 283154 (1990-10-01), None
patent: 4216200 (1993-11-01), None
patent: 0 091 543 (1983-10-01), None
patent: 0 119 476 (1984-02-01), None
patent: 0139 676 (1984-08-01), None
patent: 0 064 063 (1985-09-01), None
patent: 0 332 084 (1989-09-01), None
patent: 0 158 420 (1990-11-01), None
patent: 0 431 950 (1991-06-01), None
patent: 0 050 129 (1992-03-01), None
patent: 1 236 800 (2002-09-01), None
patent: 2657881 (1991-08-01), None
patent: 2111527 (1983-07-01), None
patent: 1 160 544 (1985-12-01), None
patent: 2160544 (1985-12-01), None
patent: 2 195 342 (1988-04-01), None
patent: 58035122 (1983-03-01), None
patent: 58035124 (1983-03-01), None
patent: 58225028 (1983-12-01), None
patent: 61013156 (1984-06-01), None
patent: 60065000 (1985-04-01), None
patent: 61072722 (1986-04-01), None
patent: 61099828 (1986-05-01), None
patent: 61225136 (1986-10-01), None
patent: 63142000 (1988-06-01), None
patent: 4077431 (1992-03-01), None
patent: 6050971 (1994-02-01), None
patent: 8801757 (1988-09-01), None
patent: 9200051 (1992-01-01), None
patent: 1756349 (1992-08-01), None
patent: WO 82/01773 (1982-05-01), None
patent: WO 83/00693 (1983-03-01), None
patent: WO 84/03105 (1984-08-01), None
patent: WO 93/20187 (1993-10-01), None
patent: WO 95/13539 (1995-05-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 98/06431 (1998-02-01), None
patent: WO 98/28001 (1998-07-01), None
patent: WO 97/41229 (1998-11-01), None
patent: WO 99/64440 (1999-12-01), None
patent: WO 99/64461 (1999-12-01), None
patent: WO 00/32223 (2000-06-01), None
patent: WO 01/54721 (2001-08-01), None
patent: WO 01/62287 (2001-08-01), None
Rudikoff et al. Proc. Natl. Acad. Sci. USA, 1982, vol. 79, pp. 1979-1983.
Janeway et al. Immunobiology, 6th edition, Garland Science. p. 110-112.
Anonymous, “Human Interferon Alpha Subtypes, URL: http://www.researched.com/cytokines/ifnasubt.htm”Diagnostic Research, Inc.(retrieved on Nov. 25, 2002).
Jones et al., “Endocrine-Mediated Mechanisms of Fatique During Treatment with Interferon-Alpha.”Seminars in Oncology(Suppl. 1, Abstract Only) 25(1):54-63 (Feb. 1998).
Little et al., “Of Mice and Men: Hybridoma and Recombinant Antibodies.”Immunology Today21(8):364-370 (Aug. 2000).
Okanoue Takeshi et al., “Side Effects of High-Dose Interferon Therapy for Chronic Hepatitis C.”J. Hepatology(Abstract Only) 25(3):283-291 (1996).
Seifarth et al., “Augmented Immune Response to Islet Cell Anitgens and Development of Diabetes Mellitus Under Treatment with Interferon-Alpha in Chronic Hepatitis C.”Zeitschrift Fuer Gastroenterologie(Abstract Only) 37(3):235-239 (Mar. 1999).
Adolf et al., Production of Monoclonal Antibodies to human IFN-α and Their Use For Analysis of the Antigenic Composition of Various Natural InterferoJournal of Cellular Physiology Supplement2:61-68 (1982).
Aguet et al., “A crystaline synthetic peptide representing the epitope of a monoclonal antibody raised against synthetic interferon-α 1 fragment 111-116”Eur. J. Biochem.146:689-691 (1985).
Alexenko et al. “The Antiproliferative and Antiviral Activities of IFN-τ Variants in Human Cells”Journal of Interferon and Cytokine Research17:767-779 (1997).
Alkan and Braun, “Epitope mapping of human recombinant interferon alpha molecules by monoclonal antibodies”Ciba Found Symp(Nehterlands) 119:264-278 (1986).
Andersson et al., “Application of Four Anti-Human Interferon-α Monoclonal Antibodies for Immunoassay and Comparative Analysis of Natural Interferon Mixtures”Journal of Interferon Research11:53-60 (1991).
Ansell, Philip R.J. “Hybridoma technology: a view from the patent arena”Immunology Today21(8):357358 (Aug. 2000).
Bach, Jean Francois, “Insulin—Dependent Diabetes Melitus as an Autoimmune Disease”Endocrine Reviews15)4):516-542 (1994).
Baldeon et al., “interferon-α and interferon-γ differentially affect pancreatic β-cell phenotype and function”American Physiological SocietyC25-C32( 199.
Batteux et al., “FCγRII (CD32)-dependent induction of interferon-alpha by serum from patients with lupus erythematosus”Eur. Cytokine Netw., 10(4):50 513 (Dec. 1999).
Beilharz, Manfred W. Therapeutic potential for orally administered type 1 interferonsPSIT3(6):193-197 (Jun. 2000).
Berg, Kurt, “Identification, Production, andCHaracterization of Murine Monoclonal Antibody (LO-22) Recognizing 12 Native Species of Human Alpha Interferon”Journal of Interferon Research4:481-491 (1984).
Bogdan, Christian “The function of type I Interferons in antimicrobial immunity”Current Opinion in Immunology12:419-424 (2000).
Borrebaeck, Carl A.K. “Antibodies in diagnostics-from immunoassays to protein chips”Immunology Today21(8)379-357 (Aug. 2000).
Brod et al. “Ingested Interferon α suppresses Type I diabetes in non-obese diabetic mice”Diabetologia41:1227-1232 (1998).
Brod, Staley A., “Autoimmunity Is a Type I Interferon-Deficiency Syndrome Corrected by Ingested Type I IFN via the GALT Syste
Chuntharapai Anan
Kim Jin K.
Presta Leonard G.
Stewart Timothy
Genentech Inc.
Kim Yunsoo
Kowalchyk Katherine
Naik Paul
Nolan Patrick J.
LandOfFree
Anti-interferon-α antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-interferon-α antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-interferon-α antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3611314